Comparing different preparations and doses of rosehip powder in patients with osteoarthritis of the knee: an exploratory randomized active-controlled trial  by Christensen, R. et al.
Table 1
Analysis A: Result of the Randomised Trial
Variable No Brace Group Brace Group Between Groups Difference
Mean difference
(SD)
95% CI
Lower
95% CI
Upper
Mean difference
(SD)
95% CI
Lower
95% CI
Upper
Mean difference
(SE)
95% CI
Lower
95% CI
Upper
P
Change in Nominated Pain
VAS @ 6 weeks (0-100 scale)
-1.29 (19.38) -6.39 3.80 -18.16 (21.37) -23.88 -12.44 16.87 (3.82) 9.30 24.43 <0.001
Change in KOOS Pain Subscale
@ 6 weeks (100 - 0)*
2.08 (13.11) -1.28 5.43 8.78 (16.65) 4.36 13.20 -6.70 (2.75) -12.15 -1.25 0.02
Change in KOOS Symptom
Subscale @ 6 weeks(100 - 0)*
-0.34 (10.60) -3.05 2.38 7.83 (12.54) 4.51 11.16 -8.17 (2.13) -12.39 -3.95 <0.001
Change in KOOS ADL
Subscale @ 6 weeks(100 - 0)*
1.03 (12.14) -2.11 4.16 6.67 (12.30) 3.32 10.03 -5.65 (2.29) -10.19 -1.11 0.02
Change in KOOS QoL
Subscale @ 6 weeks(100 - 0)*
1.43 (12.10) -1.79 4.64 5.82 (14.59) 1.80 9.84 -4.39 (2.55) -9.45 0.66 0.09
* Improvement in VAS pain is shown as a decrease, whereas improvement in KOOS scales are shown as an increase.
Table 2
Analysis B: Change After 12 Weeks of Bracing
Variable Both Groups Pooled
Mean
Difference
(SE)
95% CI
Lower
95% CI
Upper
P
Change in Nominated Pain
VAS @ 12 weeks (0-100 scale)
-1.55 (0.21) -1.96 -1.13 <0.001
Change in KOOS Pain
Subscale @ 12 weeks (100 - 0)*
7.95 (1.27) 5.46 10.45 <0.001
Change in KOOS Symptom
Subscale @ 12 weeks (100 - 0)*
6.82 (1.19) 4.48 9.16 <0.001
Change in KOOS ADL
Subscale @ 12 weeks (100 - 0)*
7.32 (1.12) 5.11 9.54 <0.001
Change in KOOS QoL
Subscale @ 12 weeks (100 - 0)*
8.64 (1.33) 6.02 11.26 <0.001
* Improvement in VAS pain is shown as a decrease, whereas improvement in KOOS
scales are shown as an increase.
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COMPARING DIFFERENT PREPARATIONS AND DOSES OF ROSEHIP
POWDER IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: AN
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Purpose: Alternative and complementary therapies are always of
interest to patients. Some evidence from meta-analysis indicates that
rosehip powder might reduce pain in patients with osteoarthritis (OA).
Our aim was to examine the efﬁcacy and safety of the original rosehip
powder, and two different doses of a novel enhanced rosehip powder of
selected rosehips (Rosenoids) in patients with knee OA.
Methods: This was a single-center, 12 week, double-blind, randomized,
active-controlled trial in 150 patients with symptomatic knee OA (Trial
registration: NCT01430481). Patients were stratiﬁed by sex, and
randomly assigned to receive A: ‘Original rosehip powder’ 4500mg/d (6
capsules; n¼49), B: ‘Enhanced rosehip powder’ 4500 mg/d (6 capsules;
n¼50), or C: ‘Enhanced rosehip powder’ 2250 mg/d (3 capsules; n¼51).
Patients were allowed to continue any non-opioid concomitant anal-
gesic therapy; patients were not allowed to use other rosehip prepa-
rations. The primary outcome measure was the change from baseline in
the KOOS-item ‘Pain during walking on ﬂat surface’ graded on a 5-point
Likert scale from 0 (best) to 4 (worst). Secondary outcomes included all
ﬁve KOOS subscales (Function, Quality of life, Pain, Function in sport and
recreation, and Symptoms). All statistical analyses were based on the
Intention-to-Treat (ITT) population (N¼150), replacing missing data
with Last Observation Carried Forward (LOCF) imputation. Data weremodeled and analyzed using ‘PROC MIXED’ based on REstricted
Maximum Likelihood (REML).
Results: At baseline, the average ‘Pain during walking on ﬂat surface’
was 1.3 KOOS item-points. Mean age was 65 years, with average disease
duration of 10 years. During the trial, the attrition rates were equal
across groups (A: 8%, B: 6%, and C: 8%). The change in the primary
outcome was equal across groups (P¼0.95), although the interaction
between time and group indicated a trend for some differences over
time (TimeGroup, P¼0.075). The change in ‘Pain during walking’
assessed after 12 weeks corresponded to average improvements of A
(original, 6 capsules): -0.3 (95% CI: -0.1 to -0.5; appr. 19%), B (enhanced,
6 capsules): -0.3 (-0.1 to -0.5; appr. 24%), and C (enhanced, 3 capsules):
-0.4 (-0.2 to -0.6; appr. 29%). Further, improvements from baseline in
one of the secondary outcomes at 12 weeks, KOOS-symptoms, sup-
ported treatment C - 3 capsules ‘Enhanced rosehip powder’ (8.0 [4.5 to
11.5]) compared to the ‘Original rosehip powder’ 6 capsules (2.1 [-1.4 to
5.6]): Mean difference: 5.97 (0.92 to 11.02) KOOS-symptoms subscale
points. Limitations: Although the three different formulations could be
compared and the study was masked, there was no placebo group, so
actual efﬁcacy could not be ascertained.
Conclusion: The novel ‘Enhanced rosehip powder’ (Rosenoids),
may be more potent than the other formulation (3 capsules equaled
6 capsules per day of the original formulation). This allows one
to prepare appropriate dosing regimens for phase-3-like placebo-
controlled trials.33
SERUM LEVELS OF VITAMIN D AND PARATHYROID HORMONE AND
PROGRESSION OF KNEE OA: THE OSTEOARTHRITIS INITIATIVE STUDY
F. Zhang y, J.B. Driban z, G.H. Lo x, L. Price z, S. Booth k, C.B. Eaton {, B.
Lu #, M. Nevitt yy, R. Jackson zz, C. Garganta z, M.C. Hochberg xx, C.K.
Kwoh kk, T.E. McAlindon z. y Tufts Univ., Boston, MA, USA; z Tufts Med.
Ctr., Boston, MA, USA; xBaylor Coll. of Med., Boston, MA, USA; k Jean
Mayer USDA Human Nutrition Res. Ctr. at Tufts Univ., Boston, MA, USA;
{Brown Univ., Pawtucket, RI, USA; #Harvard Univ., Boston, MA, USA;
yyUniversity of California at San Francisco, San Francisco, CA, USA;
zzOhio State Univ. Med. Ctr., Columbus, OH, USA; xxUniv. of Maryland,
Baltimore, MD, USA; kkUniv. of Pittsburgh, Pittsburgh, MA, USA
Purpose: Vitamin D deﬁciency may play a role in progression of knee
osteoarthritis (OA) but the evidence remains inconsistent and warrants
further characterization. Recent studies have suggested that peri-
articular bone changes are integral to OA onset and progression.
Vitamin D status may inﬂuence peri-articular bone, contributing to the
disease incidence and/or progression. We assessed serum levels of
vitamin D and parathyroid hormone (PTH) in association with
progression of knee OA among 488 participants of the Osteoarthritis
Initiative (OAI) Study.
Methods: Participants in the Bone Ancillary Study were recruited from
the OAI progression subcohort and had at least one knee with both
radiographic evidence of knee OA and pain. They underwent additional
knee dual-energy x-ray absorptiometry scans and knee trabecular
magnetic resonance imaging (MRI) at the 30- or 36-month (baseline)
and 48-month OAI visits (follow-up). Serum 25-hydroxyvitamin D
(25(OH)D) and PTH levels were measured at 30- or 36-month OAI visit.
